Incidence and clinical importance of lupus anticoagulant in children with recurrent upper respiratory tract infection

Basit Öğe Kaydı
dc.contributor.authorPeker E.
dc.contributor.authorKavakli K.
dc.contributor.authorBalkan C.
dc.contributor.authorKarapinar D.
dc.contributor.authorAydemir B.
dc.date.accessioned2019-10-27T08:33:56Z
dc.date.available2019-10-27T08:33:56Z
dc.date.issued2011
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: This study aims to understand the incidence and presence of lupus anticoagulant (LA) in children with recurrent upper respiratory tract infection (URTI). Methods: One hundred and sixty-five patients who were admitted to Departments of Pediatrics and Otolaryngology at Ege University Faculty of Medicine during the last 2 years and 120 age-matched healthy children as a control group were enrolled in the study. Results: The presence of LA in serum was positive in 8 (4.8%) cases in the patient group while only 2 (1.6%) cases in the healthy control group (P =.03). Mean age of patients with LA positive was significantly lower than those of negative cases (P =.02). Of the patients, 92 (55.8%) had adenoid hypertrophy. The annual frequency of URTI did not differ significantly between the LA patients and the LA-negative patients (7.5/year and 6.9/year, respectively). None of the patients with LA positive had adenoid hypertrophy (P =.009). Activated partial thromboplastin time was prolonged in 6 (3.6%) of 165 patients. Of these 6 patients, 2 were also LA positive. The presence of LA disappeared in all the 8 patients 2 months after the diagnosis. Lupus anticoagulant was found negative in all patients at the end of the second month. Conclusion: We found that the ratio of the presence of LA is higher in children with recurrent URTI than healthy children. However, the presence of LA does not lead to bleeding and/or thrombosis, and it disappears in a short period of time. © The Author(s) 2011.en_US
dc.identifier.doi10.1177/1076029609351292en_US
dc.identifier.endpage224en_US
dc.identifier.issn1076-0296
dc.identifier.issue2en_US
dc.identifier.pmid19903696en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage220en_US
dc.identifier.urihttps://doi.org/10.1177/1076029609351292
dc.identifier.urihttps://hdl.handle.net/11454/26926
dc.identifier.volume17en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofClinical and Applied Thrombosis/Hemostasisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectchilden_US
dc.subjectcoagulopathyen_US
dc.subjectlupus anticoagulanten_US
dc.subjectupper respiratory tract infectionen_US
dc.titleIncidence and clinical importance of lupus anticoagulant in children with recurrent upper respiratory tract infectionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu